Summary

The 7 major peanut allergy markets reached a value of US$ 445.4 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 939.2 Million by 2034, exhibiting a growth rate (CAGR) of 7.02% during 2024-2034.

The peanut allergy market has been comprehensively analyzed in IMARC's new report titled "Peanut Allergy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Peanut allergy, also known as peanut hypersensitivity, is a food allergy in which the immune system mistakenly identifies peanut proteins as harmful and triggers an allergic reaction. This response occurs within minutes following direct or indirect contact with peanuts. Symptoms of the ailment can range from mild, such as itching and hives, to severe, including anaphylaxis, a life-threatening reaction that can cause difficulty breathing, swelling of the throat, and a drop in blood pressure. Individuals suffering from this illness may also experience digestive problems like stomach cramps, indigestion, diarrhea, nausea, vomiting, etc. The diagnosis of peanut allergy typically involves a combination of physical examination and underlying indications. Additionally, the doctor may investigate the patient's medical history, including a family history of allergies or any known allergies. A blood workup is utilized to monitor the antibodies in the bloodstream against allergies. The healthcare provider may perform certain assessment studies, such as skin prick tests and oral food challenges, to confirm a diagnosis in the patients.

The rising incidences of allergic reactions resulting from an overactive immune system against certain substances or foods are primarily driving the peanut allergy market. In addition to this, the increasing cases of impaired skin barriers due to atopic dermatitis, leading to exposure and penetration of food allergens, are also propelling the market growth. Moreover, the widespread adoption of effective medications, such as epinephrine and antihistamines, to help manage symptoms during an allergic reaction is creating a positive outlook for the market. Apart from this, the escalating utilization of the radioallergosorbent test (RAST) to diagnose the ailment since it aids in identifying the amount of allergen-specific IgE antibodies in the blood is also bolstering the market growth. Furthermore, several key players are making substantial investments in developing novel therapies that target particular pathways to provide more effective relief of indications. This, in turn, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of oral immunotherapy, which is designed to offer durable desensitization to peanuts and reduce the risk of severe reactions, is expected to drive the peanut allergy market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the peanut allergy market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for peanut allergy and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the peanut allergy market in any manner.

Time Period of the Study

Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034

Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the peanut allergy market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the peanut allergy market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current peanut allergy marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:
Market Insights

How has the peanut allergy market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the peanut allergy market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the peanut allergy market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (​2018-2034​) of peanut allergy across the seven major markets?
What is the number of prevalent cases (​2018-2034​) of peanut allergy by age across the seven major markets?
What is the number of prevalent cases (​2018-2034​) of peanut allergy by gender across the seven major markets?
How many patients are diagnosed (​2018-2034​) with peanut allergy across the seven major markets?
What is the size of the peanut allergy patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of peanut allergy?
What will be the growth rate of patients across the seven major markets?

Peanut Allergy: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for peanut allergy drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the peanut allergy market?
What are the key regulatory events related to the peanut allergy market?
What is the structure of clinical trial landscape by status related to the peanut allergy market?
What is the structure of clinical trial landscape by phase related to the peanut allergy market?
What is the structure of clinical trial landscape by route of administration related to the peanut allergy market?

ページTOPに戻る

Table of Contents

1 Preface

2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Peanut Allergy - Introduction
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence

5 Peanut Allergy - Disease Overview
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment

6 Patient Journey

7 Peanut Allergy - Epidemiology and Patient Population
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (​2018-2034​)
7.2.4 Epidemiology by Gender (​2018-2034​)
7.2.5 Diagnosed Cases (​2018-2034​)
7.2.6 Patient Pool/Treated Cases (​2018-2034​)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (​2018-2034​)
7.3.4 Epidemiology by Gender (​2018-2034​)
7.3.5 Diagnosed Cases (​2018-2034​)
7.3.6 Patient Pool/Treated Cases (​2018-2034​)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (​2018-2034​)
7.4.4 Epidemiology by Gender (​2018-2034​)
7.4.5 Diagnosed Cases (​2018-2034​)
7.4.6 Patient Pool/Treated Cases (​2018-2034​)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (​2018-2034​)
7.5.4 Epidemiology by Gender (​2018-2034​)
7.5.5 Diagnosed Cases (​2018-2034​)
7.5.6 Patient Pool/Treated Cases (​2018-2034​)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (​2018-2034​)
7.6.4 Epidemiology by Gender (​2018-2034​)
7.6.5 Diagnosed Cases (​2018-2034​)
7.6.6 Patient Pool/Treated Cases (​2018-2034​)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (​2018-2034​)
7.7.4 Epidemiology by Gender (​2018-2034​)
7.7.5 Diagnosed Cases (​2018-2034​)
7.7.6 Patient Pool/Treated Cases (​2018-2034​)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (​2018-2034​)
7.8.4 Epidemiology by Gender (​2018-2034​)
7.8.5 Diagnosed Cases (​2018-2034​)
7.8.6 Patient Pool/Treated Cases (​2018-2034​)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (​2018-2034​)
7.9.4 Epidemiology by Gender (​2018-2034​)
7.9.5 Diagnosed Cases (​2018-2034​)
7.9.6 Patient Pool/Treated Cases (​2018-2034​)

8 Peanut Allergy - Treatment Algorithm, Guidelines, and Medical Practices
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm

9 Peanut Allergy - Unmet Needs

10 Peanut Allergy - Key Endpoints of Treatment

11 Peanut Allergy - Marketed Products
11.1 List of Peanut Allergy Marketed Drugs Across the Top 7 Markets
11.1.1 Palforzia (Peanut Allergen Powder-dnfp]) - Nestlé
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

12 Peanut Allergy - Pipeline Drugs
12.1 List of Peanut Allergy Pipeline Drugs Across the Top 7 Markets
12.1.1 CNP-201 - Cour Pharmaceutical
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Viaskin Peanut - DBV Technologies
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 VE416 - Vedanta Biosciences
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 Omalizumab - Genentech/Novartis
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 PVX-108 - Aravax
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

13. Peanut Allergy - Attribute Analysis of Key Marketed and Pipeline Drugs

14. Peanut Allergy – Clinical Trial Landscape
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events

15 Peanut Allergy - Market Scenario
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Peanut Allergy - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Peanut Allergy - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Peanut Allergy - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Peanut Allergy - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Peanut Allergy - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Peanut Allergy - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Peanut Allergy - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Peanut Allergy - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Peanut Allergy - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Peanut Allergy - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Peanut Allergy - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Peanut Allergy - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Peanut Allergy - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Peanut Allergy - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Peanut Allergy - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Peanut Allergy - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Peanut Allergy - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Peanut Allergy - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Peanut Allergy - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Peanut Allergy - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Peanut Allergy - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Peanut Allergy - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Peanut Allergy - Access and Reimbursement Overview

16 Peanut Allergy - Recent Events and Inputs From Key Opinion Leaders

17 Peanut Allergy Market - SWOT Analysis
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats

18 Peanut Allergy Market – Strategic Recommendations

19 Appendix